Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 63.58
(+49.49%)
Based on the Biohaven Pharmaceutical Holding Co Ltd stock forecast from 13 analysts, the average analyst target price for Biohaven Pharmaceutical Holding Co Ltd is USD 63.58 over the next 12 months. Biohaven Pharmaceutical Holding Co Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biohaven Pharmaceutical Holding Co Ltd is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Biohaven Pharmaceutical Holding Co Ltd’s stock price was USD 42.53. Biohaven Pharmaceutical Holding Co Ltd’s stock price has changed by +8.19% over the past week, +15.82% over the past month and -12.40% over the last year.
No recent analyst target price found for Biohaven Pharmaceutical Holding Co Ltd
No recent average analyst rating found for Biohaven Pharmaceutical Holding Co Ltd
Company Overview Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. Read Less
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neur...Read More
Frequently Asked Questions About Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock
Based on ratings from 13 analysts Biohaven Pharmaceutical Holding Co Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 26 buy, sell and hold ratings.
Unfortunately we do not have enough data on BHVN's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for BHVN is USD 63.58 over the next 12 months. The maximum analyst target price is USD 76 while the minimum anlayst target price is USD 54.
Unfortunately we do not have enough data on BHVN's stock to indicate if its overvalued.
The last closing price of BHVN's stock was USD 42.53.
The most recent market capitalization for BHVN is USD 3.93B.
Based on targets from 13 analysts, the average taret price for BHVN is projected at USD 63.58 over the next 12 months.
This means that BHVN's stock price may go up by +49.49% over the next 12 months.
We can't find any ETFs which contains Biohaven Pharmaceutical Holding Co Ltd's stock.
As per our most recent records Biohaven Pharmaceutical Holding Co Ltd has 239 Employees.
Biohaven Pharmaceutical Holding Co Ltd's registered address is 215 Church Street, New Haven, CT, United States, 06510.
You can get more information about it from Biohaven Pharmaceutical Holding Co Ltd's website at https://www.biohaven.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock
Based on ratings from 13 analysts Biohaven Pharmaceutical Holding Co Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 26 buy, sell and hold ratings.
Unfortunately we do not have enough data on BHVN's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for BHVN is USD 63.58 over the next 12 months. The maximum analyst target price is USD 76 while the minimum anlayst target price is USD 54.
Unfortunately we do not have enough data on BHVN's stock to indicate if its overvalued.
The last closing price of BHVN's stock was USD 42.53.
The most recent market capitalization for BHVN is USD 3.93B.
Based on targets from 13 analysts, the average taret price for BHVN is projected at USD 63.58 over the next 12 months.
This means that BHVN's stock price may go up by +49.49% over the next 12 months.
We can't find any ETFs which contains Biohaven Pharmaceutical Holding Co Ltd's stock.
As per our most recent records Biohaven Pharmaceutical Holding Co Ltd has 239 Employees.
Biohaven Pharmaceutical Holding Co Ltd's registered address is 215 Church Street, New Haven, CT, United States, 06510.
You can get more information about it from Biohaven Pharmaceutical Holding Co Ltd's website at https://www.biohaven.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BHVN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
